Quantcast

Latest Bosentan Stories

2008-06-20 12:00:07

SOUTH SAN FRANCISCO, Calif. and ALLSCHWIL, Switzerland, June 20 /PRNewswire/ -- Actelion Ltd announced today that data published in The Lancet(1) show that, in mildly symptomatic pulmonary arterial hypertension (PAH) patients (WHO functional class II - WHO FC II), bosentan (Tracleer(R)) prevented clinical deterioration by significantly delaying time to clinical worsening and reduced the number of patients worsening to WHO FC III/IV. A significant reduction in pulmonary vascular resistance...

2007-12-19 12:00:13

ALLSCHWIL, Switzerland, Dec. 19, 2007 (PRIME NEWSWIRE) -- Actelion Ltd. (SWX:ATLN) announced today the initiation of the phase III study SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome) for its highly potent, tissue-targeting endothelin receptor antagonist (ERA) Actelion-1 (ACT-064992). The study is designed to evaluate the safety and efficacy of Actelion-1 in delaying disease progression and mortality in patients with...

2006-03-24 20:37:36

WASHINGTON (Reuters) - Encysive Pharmaceuticals Inc.'s drug Thelin is "approvable" for treating a rare, often-fatal lung condition, a U.S. Food and Drug Administration (FDA) spokeswoman said on Friday. The FDA sent an "approvable letter" to the company saying Thelin could be approved if certain conditions were met, FDA spokeswoman Susan Cruzan said. She did not disclose the conditions. The Houston-based company is seeking permission to sell Thelin for treating pulmonary arterial...

2006-03-24 20:35:00

WASHINGTON (Reuters) - Encysive Pharmaceuticals Inc.'s drug Thelin is "approvable" for treating a rare, often-fatal lung condition, a U.S. Food and Drug Administration (FDA) spokeswoman said on Friday. The FDA sent an "approvable letter" to the company saying Thelin could be approved if certain conditions were met, FDA spokeswoman Susan Cruzan said. She did not disclose the conditions. The Houston-based company is seeking permission to sell Thelin for treating pulmonary arterial hypertension...

2005-07-26 11:27:26

WASHINGTON (Reuters) - Swiss biotechnology company Actelion's Web site for its pulmonary hypertension drug Tracleer is misleading and false, U.S. regulators warned in a letter released on Tuesday. The site "omits material facts regarding important risk information associated with the use of Tracleer, overstates the efficacy of Tracleer, makes unsubstantiated superiority claims, and contains claims that broaden the indication for Tracleer," U.S. Food and Drug Administration officials said....


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.